Type 2 Diabetes Mellitus Induced by an Atypical Antipsychotic Medication

References

1. ↵
   Lebovitz HE. Diagnosis, classification, and pathogenesis of diabetes mellitus. J Clin Psychiatry 2001; 62(Suppl 27): 5–9.
2. ↵
   The numbers count. Mental disorders in America. Bethesda, Md: National Institute of Mental Health, National Institutes of Health, 2001. NIH publication no. 01–4584.
3. ↵
   Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 2001; 11: 25–32.

   OpenUrlCrossRefPubMedWeb of Science
4. ↵
   Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001; 62(Suppl 27): 15–26.
5. Henderson DC, Cagliero F, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000; 157: 975–81.

   OpenUrlCrossRefPubMedWeb of Science
6. McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 2001; 46: 273–81.

   OpenUrlPubMedWeb of Science
7. ↵
   Ardizzone TD, Bradley RJ, Freeman AM 3rd, Dwyer DS. Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine. Brain Res 2001; 923: 82–90.

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   Bonanno DG, Davydov L, Botts SR. Olanzapine-induced diabetes mellitus. Ann Pharmacother 2001; 35: 563–5.

   OpenUrlAbstract/FREE Full Text
9. ↵
   Goldstein LE, Sporn J, Brown S, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999; 40: 438–43.

   OpenUrlPubMedWeb of Science
10. ↵
    Kato MM, Goodnick PJ. Antipsychotic medication: effects on regulation of glucose and lipids. Expert Opin Pharmacother 2001; 2: 1571–82.

    OpenUrlCrossRefPubMed
11. ↵
    Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285: 2486–97.

    OpenUrlCrossRefPubMedWeb of Science
12. ↵
    Woosley R. Drug labeling revisions—guaranteed to fail? JAMA 2000; 284: 3047–9.

    OpenUrlCrossRefPubMedWeb of Science